000134833 001__ 134833
000134833 005__ 20240229105043.0
000134833 0247_ $$2doi$$a10.1016/j.ccell.2018.04.004
000134833 0247_ $$2pmid$$apmid:29763623
000134833 0247_ $$2pmc$$apmc:PMC5956280
000134833 0247_ $$2ISSN$$a1535-6108
000134833 0247_ $$2ISSN$$a1878-3686
000134833 0247_ $$2altmetric$$aaltmetric:41388262
000134833 037__ $$aDKFZ-2018-00623
000134833 041__ $$aeng
000134833 082__ $$a610
000134833 1001_ $$aMackay, Alan$$b0
000134833 245__ $$aMolecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial.
000134833 260__ $$aCambridge, Mass.$$bCell Press$$c2018
000134833 3367_ $$2DRIVER$$aarticle
000134833 3367_ $$2DataCite$$aOutput Types/Journal article
000134833 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1660038281_23715
000134833 3367_ $$2BibTeX$$aARTICLE
000134833 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000134833 3367_ $$00$$2EndNote$$aJournal Article
000134833 520__ $$aThe HERBY trial was a phase II open-label, randomized, multicenter trial evaluating bevacizumab (BEV) in addition to temozolomide/radiotherapy in patients with newly diagnosed non-brainstem high-grade glioma (HGG) between the ages of 3 and 18 years. We carried out comprehensive molecular analysis integrated with pathology, radiology, and immune profiling. In post-hoc subgroup analysis, hypermutator tumors (mismatch repair deficiency and somatic POLE/POLD1 mutations) and those biologically resembling pleomorphic xanthoastrocytoma ([PXA]-like, driven by BRAF_V600E or NF1 mutation) had significantly more CD8+ tumor-infiltrating lymphocytes, and longer survival with the addition of BEV. Histone H3 subgroups (hemispheric G34R/V and midline K27M) had a worse outcome and were immune cold. Future clinical trials will need to take into account the diversity represented by the term 'HGG' in the pediatric population.
000134833 536__ $$0G:(DE-HGF)POF3-319H$$a319H - Addenda (POF3-319H)$$cPOF3-319H$$fPOF III$$x0
000134833 588__ $$aDataset connected to CrossRef, PubMed,
000134833 7001_ $$aBurford, Anna$$b1
000134833 7001_ $$aMolinari, Valeria$$b2
000134833 7001_ $$0P:(DE-He78)551bb92841f634070997aa168d818492$$aJones, David$$b3$$udkfz
000134833 7001_ $$aIzquierdo, Elisa$$b4
000134833 7001_ $$aBrouwer-Visser, Jurriaan$$b5
000134833 7001_ $$aGiangaspero, Felice$$b6
000134833 7001_ $$aHaberler, Christine$$b7
000134833 7001_ $$aPietsch, Torsten$$b8
000134833 7001_ $$aJacques, Thomas S$$b9
000134833 7001_ $$aFigarella-Branger, Dominique$$b10
000134833 7001_ $$aRodriguez, Daniel$$b11
000134833 7001_ $$aMorgan, Paul S$$b12
000134833 7001_ $$aRaman, Pichai$$b13
000134833 7001_ $$aWaanders, Angela J$$b14
000134833 7001_ $$aResnick, Adam C$$b15
000134833 7001_ $$aMassimino, Maura$$b16
000134833 7001_ $$aGarrè, Maria Luisa$$b17
000134833 7001_ $$aSmith, Helen$$b18
000134833 7001_ $$0P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c$$aCapper, David$$b19$$udkfz
000134833 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan$$b20$$udkfz
000134833 7001_ $$aWürdinger, Thomas$$b21
000134833 7001_ $$aTam, Rachel$$b22
000134833 7001_ $$aGarcia, Josep$$b23
000134833 7001_ $$aThakur, Meghna Das$$b24
000134833 7001_ $$aVassal, Gilles$$b25
000134833 7001_ $$aGrill, Jacques$$b26
000134833 7001_ $$aJaspan, Tim$$b27
000134833 7001_ $$aVarlet, Pascale$$b28
000134833 7001_ $$aJones, Chris$$b29
000134833 773__ $$0PERI:(DE-600)2074034-7$$a10.1016/j.ccell.2018.04.004$$gVol. 33, no. 5, p. 829 - 842.e5$$n5$$p829 - 842.e5$$tCancer cell$$v33$$x1535-6108$$y2018
000134833 909CO $$ooai:inrepo02.dkfz.de:134833$$pVDB
000134833 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)551bb92841f634070997aa168d818492$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000134833 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c$$aDeutsches Krebsforschungszentrum$$b19$$kDKFZ
000134833 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b20$$kDKFZ
000134833 9131_ $$0G:(DE-HGF)POF3-319H$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vAddenda$$x0
000134833 9141_ $$y2018
000134833 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER CELL : 2015
000134833 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000134833 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000134833 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000134833 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000134833 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000134833 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000134833 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000134833 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000134833 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000134833 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000134833 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000134833 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000134833 915__ $$0StatID:(DE-HGF)9920$$2StatID$$aIF >= 20$$bCANCER CELL : 2015
000134833 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000134833 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x1
000134833 9201_ $$0I:(DE-He78)G380-20160331$$kG380$$lKKE Neuropathologie$$x2
000134833 9201_ $$0I:(DE-He78)L201-20160331$$kL201$$lDKTK Berlin$$x3
000134833 980__ $$ajournal
000134833 980__ $$aVDB
000134833 980__ $$aI:(DE-He78)B062-20160331
000134833 980__ $$aI:(DE-He78)L101-20160331
000134833 980__ $$aI:(DE-He78)G380-20160331
000134833 980__ $$aI:(DE-He78)L201-20160331
000134833 980__ $$aUNRESTRICTED